05:00 EDT Precigen (PGEN) jumps 32% to $2.44 after FDA approval of Papzimeos
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGEN:
- FDA approves Precigen immunotherapy for respiratory papillomatosis
- Precigen trading halted, news pending
- Precigen’s Transformative Potential: Buy Rating Backed by Imminent FDA Decision and Strong Financial Outlook
- Precigen, Inc. Reports Q2 2025 Earnings and Strategic Focus
- Is PGEN a Buy, Before Earnings?